Request Sample Form

Name*:

Phone No.*:

Email*:

Service Intersted In:

Download Complete Report

Your Name*:

Email*:

Contact Number*:

Subject*:

Service Interested In* (required)

Your Requirment*:

Nucala (mepolizumab) gains FDA approval for two new self-administration options

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate.

June 7th, 2019|News|

Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care

Novartis has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra® (lifitegrast ophthalmic solution) 5% worldwide.

May 14th, 2019|News|

Phytosphingosine in Dental Care

In a recent study, the effect of phytosphingosine on bacterial biofilm has been evaluated. Results from this study shows that phytosphingosine has strong anti-adherence and anti-biofilm property and it could be used for oral microbial control i.e. either prevention or for therapeutic purposes in oral care products, such as toothpaste and mouth rinses.

May 9th, 2019|Blog|

AZ announces Phase I DS-8201 results

AstraZeneca has announced two Lancet Oncologypublications of its Phase I dose-expansion results of DS-8201 (trastuzumab deruxtecan) in HER2-positive metastatic breast and gastric cancer.

May 2nd, 2019|News|

ViiV submits NDA for first long-acting, injectable HIV combo

ViiV Healthcare has submitted a new drug application to the US Food and Drug Administration (FDA) for the first ever monthly, injectable, two-drug regimen of cabotegravir and Edurant (rilpivirine) for treatment of HIV.

May 1st, 2019|News|

Bayer, Orion win FDA priority review for darolutamide in prostate cancer

The US Food and Drug Administration (FDA) has accepted a new drug application for review and granted priority review for darolutamide.

May 1st, 2019|News|

Oral Administration of Insulin

Oral administration of insulin is gaining much interest nowadays as it offers various benefits such as versatility, bio compatibility, protective effect against enzymatic degradation, and cell-specific targeting.

April 25th, 2019|Blog|

Eli Lilly has announced that its humanised monoclonal antibody, Taltz (ixekizumab), yielded good results in a Phase III trial

Eli Lilly has announced that its humanised monoclonal antibody, Taltz (ixekizumab), yielded good results in a Phase III trial.

April 23rd, 2019|News|

EVENITY™ (romosozumab-aqqg) now available in the United States for the treatment of osteoporosis in postmenopausal women at high risk for fracture

Amgen (NASDAQ: AMGN) announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S.

April 16th, 2019|News|

Fluid nourishing tumor cells

The substance that bathes tumors in the body is quite different from the medium used to grow cancer cells in the lab, biologists report.

April 16th, 2019|News|